Related Experiment Video
Updated: Aug 19, 2026
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
[Development of purified HFRS bivalent vaccine]
Shi-long Yang1, Guan-mu Dong, Juan Li
1Lanzhou Institute of Biological Products, Lanzhou 730046, China. yangsl186@sohu.com
Aim:
To develop the purified HFRS bivalent vaccine.
Methods:
LR1 (type I) and R22 (type II) of HFRS virus were cultured respectively in Vero cells. The viral suspensions were harvested, inactivated with beta-propiolactone, concentrated by ultra-filtration, purified by zone centrifugation, and desucrosed by column chromatography. The qualified vaccine bulks of type I and type II were mixed equally and absorbed with AI(OH)3 for preparation of 3 lots vaccines.
Results:
The 3 lots vaccines all passed examination carried out by ourselves and reexamination performed by National Institute for the Control of Pharmaceutical and Biological Products . One of 3 lots has been used in clinical trial.
Conclusion:
It is practical to develop the purified HFRS bivalent vaccine by Vero cell culture.
